R-5780-01 与 PD-1 检查点抑制剂(称为 T 细胞的免疫细胞上的检查点蛋白)联合治疗实体瘤患者
R-5780 与 PD-1(称为 T 细胞的免疫细胞上的检查点蛋白)通路检查点抑制剂联合用于实体瘤患者的单次和重复给药和扩展研究的安全性、药物暴露和临床活性
The goal of this study is determine the safety and tolerability of orally taken probiotic (R-5780) in patients currently on a PD-1 Pathway Checkpoint Inhibitor (checkpoint protein on immune cells called T cells) with Solid Tumors.
研究概览
详细说明
Patients will take an oral dosage of probiotic (R-5780 and provide patient reported overall feeling and physician scored measure of their tumors. Blood and fecal evaluations of inflammation and assessment of probiotic (R-5780) on fecal levels will also be measured.
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Janet Stephens, PhD
- 电话号码:650-417-8556
- 邮箱:jstephens@risetherapeutics.com
研究联系人备份
- 姓名:Christian Freguia, PhD
- 电话号码:215-923-1818
- 邮箱:cfreguia@risetherapeutics.com
学习地点
-
-
Colorado
-
Denver、Colorado、美国、80218
- 招聘中
- Sarah Cannon Research Institute
-
首席研究员:
- Gerald Falchook, MD
-
接触:
- Tamara Davidson
- 电话号码:720-667-7459
- 邮箱:Tamara.Davidson@sarahcannon.com
-
-
Tennessee
-
Nashville、Tennessee、美国、37203
- 招聘中
- Sarah Cannon Research Institute
-
首席研究员:
- Benjamin Garmezy, MD
-
接触:
- Sam Howell
- 电话号码:615-478-2104
- 邮箱:sam.howell@scri.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- At least 18 years of age to 80
- Ability to provide written informed consent
- Unresectable stage III or stage IV melanoma, basal cell carcinoma, or squamous cell carcinoma as per the American Joint Committee on Cancer 2017 Guidelines (8th Edition) regardless of BRAF mutation status and other solid tumors.
- Refractory to anti-PD (checkpoint Protein on Immune Cells called T cells)-1/L1 therapy per RECIST v1.1 defined as subject who has disease progression after receiving at least two complete cycles of ICI (immune checkpoint inhibitors) therapy or disease progression 6 months from initiation of ICI (immune checkpoint inhibitors) therapy while still on active therapy.
- Life expectancy of greater than 3 months
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
- Subjects must have evaluable disease by CT (computer tomography) or MRI (magnet resonance imaging) per RECIST 1.1 criteria or clinically apparent disease that the investigator can follow for response.
Exclusion Criteria:
- Any serious medical condition or laboratory abnormality or psychiatric condition or any other significant or unstable concurrent medical illness (in the opinion of the Investigator) would preclude protocol adherence or would make the safety of the study drug difficult to assess
- Treatment with systemic broad-spectrum antibiotics.
- No active viral infections.
- Coexisting severe chronic diseases other than cancer (autoimmunity, inflammatory diseases)
- Secondary gastrointestinal motility disorders
- History of solid organ transplant or bone marrow transplant
- Prior CAR-T (chimeric antigen receptor) or allogeneic cellular therapy
- Ongoing systemic immunosuppressive therapy, with the exclusion of prednisone (10 mg/day)
- Concurrent therapy with any other investigational agent, vaccine, or device
- Pregnant or breastfeeding or planning to conceive or father a child during the trial period
- Subjects with untreated brain metastasis. Treated brain metastasis are permitted if stable
- More than 4 prior systemic therapies
- Other cancer medications during treatment period are not permitted
- Enrollment in other clinical trials.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
其他:Open Label
R-5780 Probiotic |
Probiotic |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence and severity of adverse events and their relationship to R-5780 (probiotic) administration
大体时间:Baseline through Week 4
|
To assess the number of participants with treatment-related adverse events after taking R-5780 (probiotic) |
Baseline through Week 4
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Scale (QOLS)
大体时间:Baseline through End of Study Day 112
|
Collect how the patient is feeling on each study visit on the Quality of Life Scale of 30 questions. The Quality of Life scores are summed so that a higher score indicates higher quality of life. |
Baseline through End of Study Day 112
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.